Compliance Rate
Compliance Rate
47.32%
Compliant submissions
53
Incompliant submissions
59
Total trials
112
My Organizations' Clinical Trials
Showing 1125 of 1129 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/31/86
End: 11/30/91
Due: 11/30/92
Phase: N/A
Priority: Normal
Start: 08/01/09
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 08/31/10
End: 09/30/14
Due: 09/30/15
Phase: N/A
Priority: Normal
Start: 09/30/95
End: 08/31/01
Due: 08/31/02
Phase: N/A
Priority: Normal
Start: 07/31/94
End: 05/31/98
Due: 05/31/99
Phase: N/A
Priority: Normal
Start: 04/30/07
End: 11/30/12
Due: 11/30/13
Phase: N/A
Priority: Normal
Start: 09/30/96
End: 08/31/98
Due: 08/31/99
Phase: N/A
Priority: Normal
Start: 04/30/00
End: 07/31/00
Due: 07/31/01
Phase: N/A
Priority: Normal
Start: 09/30/86
End: 09/30/95
Due: 09/30/96
Phase: N/A
Priority: Normal
Start: 10/31/06
End: 03/31/10
Due: 03/31/11
Phase: N/A
Priority: Normal
Start: 08/31/08
End: 10/31/11
Due: 10/31/12
Phase: N/A
Priority: Normal
Start: 01/27/09
End: 10/24/11
Due: 10/24/12
Phase: N/A
Priority: Normal
Start: 09/30/00
End: 07/31/05
Due: 07/31/06
Phase: N/A
Priority: Normal
Start: 09/30/83
End: 08/31/91
Due: 08/31/92
Phase: N/A
Priority: Normal
Start: 02/19/08
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 09/30/00
End: 08/31/05
Due: 08/31/06
Phase: N/A
Priority: Normal
Start: 09/30/88
End: 12/31/05
Due: 12/31/06
Phase: N/A
Priority: Normal
Start: 06/15/20
End: 03/15/22
Due: 03/15/23
Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies
Phase: N/A
Priority: Normal
Start: 03/24/22
End: 06/01/35
Due: 06/01/36
Phase: N/A
Priority: Normal
Start: 05/31/91
End: 04/30/92
Due: 04/30/93
Phase: N/A
Priority: Normal
Start: 02/08/14
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 07/31/18
End: 07/31/25
Due: 07/31/26
Phase: N/A
Priority: Normal
Start: 07/31/98
End: 06/30/02
Due: 06/30/03
Phase: N/A
Priority: Normal
Start: 11/15/24
End: 05/15/27
Due: 05/15/28
Phase: N/A
Priority: Normal
Start: 09/30/93
End: 03/31/97
Due: 03/31/98